Sobi Taps AstraZeneca's RSV Therapies, Both Current And Future, For US Expansion

 
• By John Davis
  
Generate a summary of this article
Listen to this article
Beta

Swedish Orphan Biovitrum gains a boost to its US commercialization infrastructure, a product to make immunology a key part of its specialty care business, and financial flexibility to seek further product acquisitions, through an RSV products deal with AstraZeneca.  

Statue of Liberty
Shining A Light On Sobi's Growth In The US • Source: Shutterstock

Swedish Orphan Biovitrum AB's agreements to acquire US rights to AstraZeneca PLC's RSV prophylactic, Synagis (palivizumab), and to participate in future earnings from a candidate RSV prophylactic therapy, MEDI8897, may keep the Swedish company active in the pediatrics/immunology sector for a much longer time than a more straightforward licensing agreement, and allow Sobi's to pursue further in-licensing deals.

For AstraZeneca, the deal continues a series of product divestments as the big pharma focuses increasingly on oncology and a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.